Difficult to Diagnose Rare Diffuse Lung Disease presents the theoretical basis and practical aspects of differential diagnosis of rare lung diseases with the use of new method of probe-based confocal laser endomicroscopy (alveoscopy) of the distal respiratory region. Each chapter describes signs and symptoms of the disease and its typical and atypical manifestations. The book contains full color illustrations including high-resolution histological microphotographs, CT-scans and confocal laser endomicroscopy images. Combined these elements make Difficult to Diagnose Rare Diffuse Lung Disease an invaluable reference and guide for pulmonary researchers, pulmonologists, radiologists, and pathologists who wish to broaden their spectrum of knowledge in rare lung diseases.
- Highlights the new method of probe-based confocal laser endomicroscopy (alveoscopy) of the distal respiratory region, opening new horizons in the minimally invasive diagnosis of lung diseases
- Each chapter discusses current treatment strategies in accordance with clinical guidelines including data from the latest clinical trials
- The differential diagnosis of each disease is presented in tabular format to aid in the diagnostic process
1. CT assessment of diffuse lung disease 2. Idiopathic interstitial pneumonia 3. Hypersensitivity pneumonitis 4 Airspace-predominant diseases 5. Pulmonary amyloidosis 6: Granulomatosis with polyangiitis 7. Eosinophilic lung disease 8. Lung disease related to connective tissue diseases 9. Diffuse cystic lung diseases 10. Lung tumors mimicking diffuse non-neoplastic lung diseases 11. Drug-induced pulmonary disease
Professor Averyanov is the head of the Pulmonary Division and Head of the Biotechnology Department at the Federal Research Clinical Center FMBA of Russia in Moscow. He is a member of the European Respiratory Society, American Thoracic Society, and Presidium of Russian National Society on Regenerative Medicine. He has lead 17 Clinical and 3 experimental trials in the field of emphysema, COPD, ?-1 antitripsin deficiency, idiopatic intersticial pneumonias, lung cancer, systemic sclerosis, alveolar proteinosis and stem cells technologies.